Lupine Publishers: Lupine Publishers | Somatic Mutations in Cancer-Fr...

Lupine Publishers: Lupine Publishers | Somatic Mutations in Cancer-Fr...: Lupine Publishers | Open Access Journal of Oncology and Medicine Abstract Somatic mutations have been perceived as the causal even...

Comments

Post a Comment

Popular posts from this blog

May Gastrointestinal and Sensory Manifestations be related to Worse COVID-19 Phenotypes

  Abstract Extra pulmonary symptoms may contribute to poor outcome in COVID-19. We compared the frequency of gastrointestinal and sensory manifestations (GSM) between mild and severely ill patients with COVID-19, alone or combined with classic respiratory manifestations (CRM). Hospitalized patients with COVID-19 (n = 357) were classified according to their disease severity by using a neutrophile/lymphocyte ratio value ≥18 for severe illness. Presence of CRM and baseline clinical data were recorded. Presence of >3 liquid evacuations per day (diarrhea), decreased usual bowel movements (constipation), nausea/vomiting, lack of appetite (anorexia), abdominal pain, loss of taste (dysgeusia) and/or loss of smell (anosmia) were personally recorded by the investigators at the study admission. Severely ill patients (47.3%) presented worse clinical markers than mildly ill patients, including higher risk of malnutrition and higher need for non-invasive respiratory support ...
Read more

Different Toxicity of Aristolochic Acids in Kidney and Liver

  Introduction Aristolochic acid (AAs) is a group of nitrophenanthrene compounds comprised of AAI, AAII, AAIII and AAIV, which are widely found in Aristolochia plants and used in herbal therapy and traditional Chinese medicine [1]. Consistent use of aristolochic acids- containing drugs could lead to aristolochic acid nephropathy and subsequent urinary tract tumors [2-4]. Active metabolites of AAs form adducts with DNA, inducing characteristic A-T transversion (A:T to T:A mutation) known as AA mutational signature [5]. In 2017, a study has analyzed AA mutational signature of several datasets and concluded that AAs and their derivatives were widely implicated in liver cancers in Taiwan and throughout Asia [6]. Ever since the paper published, there has been an intensive debate on whether the prevalence of AA signature mutation is high in HCC patients and if this mutation spectra is really correlate with traditional Chinese medicine consumption in Asia. Since no case report...
Read more

The Use of Sodium-Glucose Cotransporter 2 Inhibitors in Non-Alcoholic Fatty Liver Disease

  Opinion Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of progressive liver abnormalities from simple hepatic steatosis to non-alcoholic steatohepatitis (NASH) to advanced fibrosis, cirrhosis, and/or hepatocellular carcinoma [1]. Parallel to the rising burden of obesity and metabolic syndrome, NAFLD has emerged as the leading cause of chronic liver disease at an estimated global prevalence of 24% [2]. Besides its known clinical burden for liver-related morbidity and mortality, NAFLD is potentially linked with other extra-hepatic chronic diseases and may be considered a multisystem condition. Particularly, NAFLD increases the risk of type 2 diabetes, cardiovascular diseases, chronic kidney disease, and all-cause mortality [1]. Potential pathophysiologic mechanisms underlying the detrimental effects of NAFLD include hyperglycemia, systemic inflammation, and increased oxidative stress [3]. Sodiumglucose cotransporter 2 (SGLT2) inhibitors are a new class of ...
Read more